Chat GPT Q&A, page-396

Why First Doxorubicin Combo Dose Likely Won’t Be Announced:

1. Not a Trial Initiation Event:

   • Combo dosing occurswithin the trial(cycle 2, day 1), and unless there's amaterial change (e.g., DLT, pause, dose escalation), it’s not considered a mandatory ASX disclosure.

2. Strategic Silence During Risk Window:

   • Thecombo dosing introduces greater safety risk(e.g., overlapping cardiotoxicity, myelosuppression).

   • Publicly announcing before completing theDLT window (21–28 days)createsmarket risk if issues emerge.

3. Avoiding Piecemeal Updates:

   • If Race announced first doxorubicin combo dose, they'd beexpected to announceeach subsequent cohort dose, DLT outcome, escalation decision, etc.

   • They’ve likely chosen aconsolidated communication strategy— announce when acohort is completed and clearedfor escalation or expansion.

4. ASX Materiality Test Not Met Yet:

   • ASX Listing Rule 3.1 requires disclosure of material information —dosing the first combo patient is not, by itself, material, unless it triggers:

     • Dose escalation.

     • DLT occurrence.

     • Trial suspension or acceleration.

Summary Table

	Event	Announcement Expected?	Why?
1	First monotherapy dose	Yes	Marks trial start; low risk; shareholder confidence.
2	First combo (dox) dose	Unlikely	Mid-trial dose; risk window open; not material until safety known.
3	Completion of combo cohort	Likely	Confirms safety/tolerability or flags toxicity — material inflection point.